Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $7.1620, but opened at $6.70. Oxford BioMedica shares last traded at $6.70, with a volume of 3,000 shares traded.
Analysts Set New Price Targets
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.
Get Our Latest Stock Report on OXBDF
Oxford BioMedica Price Performance
About Oxford BioMedica
Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.
Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.
Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.
Further Reading
- Five stocks we like better than Oxford BioMedica
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
- Why Light Is the New AI Bottleneck—And 3 Photonics Stocks to Play It
- Nasdaq’s Business Is Outrunning Its Stock
- Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
